SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Ondas, Inc. engages in the development, marketing, and sale of wireless radio systems for secure, wide area mission-critical business-to-business networks. It operates through the Ondas Networks and Ondas Autonomous Systems segments. The Ondas Networks segment provides wireless connectivity solutions enabling mission-critical Industrial Internet applications and services. The Ondas Autonomous Systems segment designs, develops, and markets commercial drone solutions via the Optimus System and Scout System. The company was founded on December 22, 2014 and is headquartered in West Palm Beach, FL.

Ondas Inc.

Ondas Inc

Ondas is trending as investors digest record financial results, highlighted by a significant year-over-year revenue surge and an accelerated path toward profitability that has energized long-term shareholders. Community discussion is currently dominated by debates over the company's valuation, the impact of historical share dilution, and the potential for a short squeeze as institutional interest grows alongside the expanding backlog of defense and drone infrastructure contracts.

Intuitive Machines, Inc. is a space exploration, infrastructure, and services company, which engages in contributing to the establishment of cislunar infrastructure and helping to develop cislunar and deep space commerce. It offers space products and services. The company was founded by Stephen J. Altemus, Kam Ghaffarian, and Timothy P. Crain in 2013 and is headquartered in Houston, TX.

Intuitive Machines Inc - Ordinary Shares - Class A

Intuitive Machines Inc

Intuitive Machines is surging as investors cheer its record revenue, positive EBITDA, and strategic acquisition of Goonhilly Earth Station. The stock is a focal point of intense community debate, with bulls citing multi-year growth potential and upcoming contract catalysts, while others monitor the volatility surrounding its high-volume price swings.

CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and conditions. The company was founded by Antony E. Pfaffle on July 28, 2006 and is headquartered in Berkeley Heights, NJ.

CorMedix Inc

CorMedix is trending as investors digest the company's recent Q1 earnings results and updated full-year guidance, while also closely monitoring progress on the commercial rollout of DefenCath and anticipation for clinical data on Rezzayo. Community discussion is focused on the impact of management's profitability turnaround, the effectiveness of ongoing share buyback efforts, and the potential for long-term growth as the company navigates reimbursement dynamics.

AST Spacemobile, Inc. engages in building a broadband cellular network in space to operate directly with standard, unmodified mobile devices based on an extensive IP and patent portfolio. It focuses on providing mobile broadband services with global coverage to all end-users, without the need to purchase special equipment. The company was founded by Abel Avellan on May 31, 2017 and is headquartered in Midland, TX.

AST SpaceMobile Inc - Ordinary Shares - Class A

AST SpaceMobile Inc

AST SpaceMobile is attracting significant attention as investors weigh recent revenue misses and satellite deployment delays against a record-high short interest and major endorsements from institutional players like BlackRock. The community remains deeply polarized, with bulls pointing to upcoming mid-June satellite launches and long-term partnerships with major carriers as primary catalysts, while bears focus on execution risks and the gap between current valuation and realized revenue.

Klarna Group Plc is a global digital bank and flexible payments provider. It operates through an AI-powered payments and commerce network that empowers people to pay smarter, with a mission to be available everywhere, for everything. The company was founded by Gustav Erik Niklas Adalberth, Karl Anders Victor Jacobsson, and Sebastian Marcin Siemiatkowski in 2005 and is headquartered in London, the United Kingdom.

Klarna Group plc

Klarna is attracting significant community attention as investors weigh its ongoing growth and strategic partnerships with major tech platforms against a backdrop of high short interest. Market participants are closely watching the upcoming antitrust verdict involving its PriceRunner subsidiary, which many believe could serve as a major catalyst for the stock.

Candel Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. Its pipeline includes CAN-2409 and CAN-3110. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.

Candel Therapeutics Inc

Candel Therapeutics is trending as investors rally ahead of a high-profile plenary session at the AUA Annual Meeting, where the company will present extended clinical data for its lead prostate cancer asset. The community is actively discussing the potential for a significant rerating or buyout, while heightened short interest and strong volume drive speculation regarding a possible short squeeze.

Strive, Inc. engages in the provision of an asset management Bitcoin treasury. It is focused on maximizing value for shareholders, accumulating bitcoin and outperforming bitcoin over the long run. The company was founded by Arshia Sarkhani, Jackson Fairbanks, Arman Sarkhani, and Kyle Fairbanks on March 9, 2022 and is headquartered in Dallas, TX.

Strive Inc. - Ordinary Shares - Class A

Strive Inc.

Strive Inc. is currently rallying as investors digest the launch of daily dividends on its SATA preferred stock alongside a robust increase in Bitcoin treasury holdings. The community is actively discussing the company's debt-free status and the potential for these daily yields to drive institutional interest, fueling bullish speculation about the stock's future performance.

Paramount Skydance Corp. is a next-generation global media and entertainment company that engages in providing content creation and distribution services. It operates through the following business segments: Studios, Direct-to-Consumer, and TV Media. Its portfolio unites brands including Paramount Pictures, Paramount Television, CBS, CBS News, Nickelodeon, MTV, BET, Comedy Central, Showtime, Paramount Plus, Pluto TV, and Skydance’s Animation, Film, Television, Interactive/Games, and Sports divisions. The company was founded on June 3, 2024 and is headquartered in New York, NY.

Paramount Skydance Corp. - Ordinary Shares - Class B

Paramount Skydance Corp. ($PSKY) is currently a major focal point as investors closely watch the Warner Bros. Discovery ($WBD) merger process, with the community actively debating the company's valuation, potential shareholder dilution, and the long-term impact of its debt load. Investors are expressing significant frustration over recent price volatility and perceived lack of transparency, while balancing skepticism toward executive compensation against high hopes for the company's future as an AI-integrated media powerhouse.

Figma, Inc. is an AI-powered digital design and product development platform. The firm offers tools for teams to collaborate on the entire lifecycle of software creation. Its products include FigJam, Figma Slides, Figma Design, Figma Draw, Dev Mode, Figma Sites, Figma Buzz and Figma Make. The company was founded by Dylan Joseph Field and Evan Darrow Wallace in 2012 and is headquartered in San Francisco, CA.

Figma Inc. - Ordinary Shares - Class A

Figma

Figma is trending due to anticipation surrounding upcoming earnings, with active community debate over whether AI integration will act as a growth catalyst or a risk to its business model. Investors are closely monitoring high short interest, fueling intense speculation about a potential short squeeze alongside broader discussions on the stock's long-term valuation compared to its software peers.

Fermi, Inc. engages in the development of energy infrastructure. It intends to develop an energy and data center development campus to support the needs of to-be-built AI infrastructure. The company was founded by Rick Perry, Toby Neugebauer and Griffin Perry on January 10, 2025 and is headquartered in Amrillo, TX.

Fermi Inc

Fermi LLC

Fermi is seeing intense volatility and aggressive call volume as investors react to the sudden departure of the co-founder CEO and a broader executive shakeup. While some members of the community view the leadership transition as a necessary step to secure pending tenant agreements, others are raising concerns about the company's lack of revenue and potential for further downside.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Chasing the Next Explosive Small-Cap Run

Risk appetite came roaring back and several companies standing out, as market participants rotated heavily into sectors tied to transformative technologies and high-growth macro trends. $TGNT, $QUCY, $AEHL, $TDIC, $WGRX, $ERNA, $SLS, $WHWK

Ernexa Stock Is Jumping Today: What's Going On?

Ernexa Therapeutics Inc (NASDAQ:ERNA) shares are surging Tuesday after an investor segment and renewed focus on ERNA 101 in ovarian cancer.read more...

<ul class="summary-bullets"><li>Loss per share narrowed to $6.95 from a loss of $57.76 per share last year.</li><li>Last week, the firm said its therapy completely cleared tumors and achieved 100% long-term survival in syngeneic ovarian cancer models.</li><li>CEO Sanjeev Luther said the company remains on track to submit an Investigational New Drug application in the third quarter of 2026</li></ul>Shares of Ernexa Therapeutics Inc. (ERNA) extended their explosive rally on Tuesday, soaring more than 90% as investors piled into the biotech stock following a sharp narrowing of first-quarter losses and growing optimism around its promising ovarian cancer cell therapy program.Ernexa Therapeutics reported a first-quarter net loss of $5.51 million, narrower than the $8.20 million loss in the previous corresponding period. The company also posted a sharp improvement in loss per share, which narrowed to $6.95 from $57.76 a year earlier.Trading in <a href="https://stocktwits.com/symbol/ERNA">ERNA shares</a> was halted seven times after the opening bell, <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.nyse.com/trade/trading-halts">according</a> to NYSE data.<h2 class="st-heading-2">Retail Can’t Stop Talking About ERNA’s Ovarian Cancer Trial Results</h2>Retail sentiment for ERNA shares on Stocktwits remained in the ‘extremely bullish’ territory, while message volumes increased by around 280% over a 24-hour period. ERNA was also among the top trending tickers on the platform.One user said the stock is a “long-term” investment, citing the trial update.<stembedurl>https://stocktwits.com/Alchemisttt/message/653084994</stembedurl>Another user said they were ‘hyper bullish’ about the trial results, but would not rule out a stock offering.<stembedurl>https://stocktwits.com/splitsoup/message/653083994</stembedurl><h2 class="st-heading-2">ERNA To File NDA BY Q3</h2>Last week, Ernexa <a href="https://stocktwits.com/news-articles/markets/equity/erna-stock-surged-ernexa-ovarian-cancer-trial/cZQzOzNReOK">said</a> its ERNA-101 therapy, combined with PD-1 immunotherapy, completely cleared tumors and achieved 100% long-term survival in syngeneic ovarian cancer models, using mice. The therapy also boosted cancer-fighting immune activity and reduced tumor burden.In a letter to shareholders on Monday, CEO Sanjeev Luther said the company remains on track to submit an Investigational New Drug (IND) application in the third quarter (Q3) of 2026 and plans to begin a Phase 1 human trial later in the year.The stock has rallied nearly 250% since the pre-clinical trial results were reported.The company implemented a 1-for-25 reverse stock split earlier this month.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/rigl-stock-jumps-short-interest-surges-to-record-high-why-is-retail-eyeing-a-further-upside/cZXXhLJReiW">RIGL Stock Jumps 15%, Short Interest Surges To Record High – Why Is Retail Eyeing A Further 40% Upside?</a> For updates and corrections, email newsroom[at]stocktwits[dot]com.

Representative image of a stock chart on black background. | Image source: Getty Images

ERNA Stock Almost Doubled In Value Today – Smashing Rally Leads To 7 Trading Halts 

Ernexa Therapeutics reported a first-quarter net loss of $5.51 million, narrower than the $8.20 million loss in the previous corresponding period.

Equity

Biotech’s Next Wave May Already be in Motion

The biotech and pharma sector is entering one of its most pivotal periods in years, where insider conviction, late-stage clinical wins, and platform technologies are converging to reshape both valuations and patient outcomes. From aggressive insider buying ahead of critical data to blockbuster Phase 3 readouts redefining entire therapeutic categories, the market is signaling that the next cycle of winners may already be taking shape. $NTHI, $ERNA, $LLY, $NVO, $REGN, $MRNA

<ul class="summary-bullets"><li>Management said the outcome exceeded the company’s expectations.</li><li>The biotech firm also announced plans to advance the therapy toward a human trial.</li><li>Ernexa had recently implemented a 1-for-25 reverse stock split.</li></ul>Shares of Ernexa Therapeutics (ERNA) surged 60% on Wednesday, as investors cheered promising preclinical results for its lead cell therapy, fueling optimism about its potential in advanced ovarian cancer treatment.The biotech firm announced plans to advance the therapy toward a first-in-human trial in patients with advanced ovarian cancer.<h2 class="st-heading-2">ERNA-101 Trial Beats Expectations</h2>In combination with PD-1 blockade immunotherapy, ERNA-101 achieved complete tumor clearance and 100% long-term survival in syngeneic ovarian cancer models, using mice, significantly outperforming either treatment alone.The study showed that ERNA-101 helped reshape the tumor microenvironment. This change boosted the activity of cancer-fighting T cells and increased immune cell infiltration into tumors. The treatment also reduced overall tumor burden and disease-related complications.Management said the outcome exceeded the company’s expectations and the results potentially shift treatment outcomes in ovarian cancer.“This approach may also extend beyond ovarian cancer, with the potential to drive meaningful responses across other immunologically ‘cold’ solid tumors characterized by highly suppressive tumor microenvironments. We believe ERNA-101 has the potential to become a foundational therapy in combination regimens, significantly expanding treatment effectiveness,” said Sanjeev Luther, President and CEO.<h2 class="st-heading-2">Peers Update</h2>Ernexa’s trial comes on the heels of Zentalis Pharmaceuticals’ (ZNTL) <a href="https://stocktwits.com/news-articles/markets/equity/sntl-stock-rally-ovarian-cancer-trial-update/cZJ0S9XRItq">interim results</a> from its study of Azenosertib oral therapy for platinum-resistant ovarian cancer. The company selected a 400 mg once-daily dose after it delivered higher response rates than the 300 mg dose with similar safety.That prompted Guggenheim to&nbsp;raise Zentalis’ price target and maintain a ‘Buy’ rating. The firm expressed confidence in the drug’s chances of success.Prior to that, the FDA approved Corcept Therapeutics’ (CORT) Relacorilant drug in combination with chemotherapy drug nab-paclitaxel, for advanced ovarian-related cancers, months ahead of schedule.<h2 class="st-heading-2">How Did Retail Traders React To ERNA’s Update?</h2>Retail sentiment for <a href="https://stocktwits.com/symbol/ERNA">ERNA</a> on Stocktwits turned ‘extremely bullish’ from ‘neutral’ a day earlier, amid ‘extremely high’ message volumes.One bullish user expects a 200% rally following the news.<stembedurl>https://stocktwits.com/BTC_Will_Hit_14K/message/652423022</stembedurl>Another user highlighted the strength behind today’s update.<stembedurl>https://stocktwits.com/jengtap/message/652443092</stembedurl>The company implemented a 1-for-25 reverse stock split earlier this week.Read also:<a href="https://stocktwits.com/news-articles/markets/equity/tgtx-stock-hits-fresh-52-week-high-retail-bullish-despite-q1-earnings-miss/cZQzBBLReOO">&nbsp;TGTX Stock Hits Fresh 52-Week High – Here’s Why Retail Is Bullish Despite Q1 Earnings Miss</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

On Monday, Deutsche Bank said CAR’s downgrade to ‘Hold’ from ‘Buy' is "purely fundamental in nature"

ERNA Stock Surged 60% Today – Here’s Why Retail Is Buzzing About Ernexa’s Ovarian Cancer Trial Results

Ernexa’s ERNA-101 achieved complete tumor clearance and 100% long-term survival in syngeneic ovarian cancer models.

Ernexa Therapeutics Stock Climbs On Breakthrough Preclinical Data

Ernexa Therapeutics, Inc. (NASDAQ:ERNA) shares are trading higher Wednesday after the company announced preclinical data showing its ERNA-101 cell therapy candidate achieved complete tumor clearance...

AI Infrastructure Booms, Biotech Breakthroughs Ignite, And Advanced Materials Race Toward Scale

From billion-dollar AI buildouts to preclinical cancer breakthroughs and other milestones, investors are being forced to reassess where the next wave of outsized returns could emerge. $ERNA, $KBLB, $EVC, $NVDA, $GLW, $AHMA

<ul class="summary-bullets"><li>ERNA-101 is designed to activate and regulate the immune system's response to recognize and attack cancer cells.</li><li>The new collaboration comes as the company looks forward to clinical trials for the cell therapy.&nbsp;</li><li>ERNA-101 has shown potential to reprogram immunologically "cold" tumors into "hot" ones, increasing immune cell infiltration and suppressing tumor growth in preclinical studies. &nbsp;</li></ul><blockquote>Shares of Ernexa Therapeutics (ERNA) traded 48% higher on Wednesday afternoon after Cellipont Bioservices announced that it has entered into a collaboration with the company.</blockquote>Cellipont is a cell therapy contract development and manufacturing organization. Its <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.prnewswire.com/news-releases/cellipont-bioservices-and-ernexa-therapeutics-enter-cell-therapy-manufacturing-partnership-to-advance-erna-101-toward-clinical-trials-in-ovarian-cancer-302597673.html">partnership</a> with Ernexa will focus on activities to advance Ernexa’s lead cell therapy called ERNA-101 for the treatment of ovarian cancer into clinical manufacturing and trials.<blockquote>"Cellipont brings deep technical capabilities and a shared sense of urgency to help us translate the promise of ERNA-101 into a clinically viable therapy."&nbsp; -Sanjeev Luther, CEO, Ernexa Therapeutics.</blockquote><h2 class="st-heading-2">About The Cell Therapy</h2>ERNA-101 is designed to activate and regulate the immune system's response to recognize and attack cancer cells. According to Cellipont, it provides a scalable, off-the-shelf treatment, without needing patient-specific cell harvesting, provided it is an allogeneic iMSC therapy using stem cells from a healthy donor rather than the patient themselves.ERNA-101 has shown potential to reprogram immunologically "cold" tumors into "hot" ones, increasing immune cell infiltration and suppressing tumor growth in preclinical studies, the company said. The new collaboration comes as the company looks forward to clinical trials for the cell therapy.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/ERNA">ERNA stock</a> jumped from ‘bearish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘low’ to ‘extremely high’ levels.A Stocktwits user expressed optimism for the stock hitting a new high.<stembedurl>https://stocktwits.com/Roza11/message/634186263</stembedurl>Another, however, sees upcoming dilution.<stembedurl>https://stocktwits.com/Tradebub/message/634144629</stembedurl>ERNA stock is down by 58% this year and by 89% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/bridgebio-shares-second-postive-late-stage-study-results-in-a-week-calcium-disorder-drug-trial-yields-positive-results/cLGZvEeR3DT">BridgeBio Shares Second Positive Late-Stage Study Result In A Week – Calcium Disorder Drug Trial Yields Positive Results</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

ERNA Stock Rallies On Collaboration With Contract Manufacturer To Advance Lead Cell Therapy Into Clinical Trials 

The partnership will focus on activities to advance Ernexa’s lead cell therapy called ERNA-101 for the treatment of ovarian cancer into clinical manufacturing and trials. 

Cellipont Bioservices and Ernexa Therapeutics Enter Cell Therapy Manufacturing Partnership to Advance ERNA-101 Toward Clinical Trials in Ovarian Cancer

Cellipont Bioservices and Ernexa Therapeutics Enter Cell Therapy Manufacturing Partnership to Advance ERNA-101 Toward Clinical Trials in Ovarian Cancer Cellipont Bioservices and Ernexa Therapeutics...

Shares of Ernexa Therapeutics (ERNA) fell 13% on Tuesday morning after the company <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/06/10/3096816/0/en/Ernexa-Therapeutics-Announces-1-for-15-Reverse-Stock-Split.html">announced</a> a reverse stock split to regain compliance with the $1 minimum bid price required for continued listing on Nasdaq.The reverse stock split will be at a ratio of 1-for-15, effective June 12, 2025, at 12:01 a.m. Eastern Time. The company’s common stock is expected to begin trading on a split-adjusted basis when the market opens on June 12.As a result of the reverse stock split, every 15 shares of the company’s common stock issued and outstanding will be automatically reclassified into one new share of common stock.No fractional shares will be issued in connection with the reverse stock split, and no cash or other consideration will be paid in connection with any fractional shares.As of Tuesday, the company had 110.4 million shares of common stock issued and outstanding, which it anticipates will result in approximately 7.4 million shares of common stock issued and outstanding on a split-adjusted basis.Ernexa also stated that it believes the reverse stock split is a key step in strengthening its financial foundation and maintaining access to the capital markets needed to advance its clinical programs.Ernexa is developing innovative stem cell therapies for the treatment of advanced cancer and autoimmune disease.On Stocktwits, retail sentiment around Ernexa improved from ‘extremely bearish’ to ‘bearish’ territory over the past 24 hours while message volume remained at ‘high’ levels.<figure class="image"><img style="aspect-ratio:629/57;" src="https://news.stocktwits-cdn.com/Screenshot_2025_06_10_at_10_35_28_AM_png_969f4ebcc6.webp" alt="ERNA's Sentiment Meter and Message Volume as of 10:30 a.m. ET on June 10, 2025 | Source: Stocktwits" width="629" height="57"><figcaption>ERNA's Sentiment Meter and Message Volume as of 10:30 a.m. ET on June 10, 2025 | Source: Stocktwits</figcaption></figure><a href="https://stocktwits.com/symbol/ERNA">ERNA stock</a> is down by about 56% this year and by about 91% over the past 12 months.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/tencent-music-expands-audio-empire-with-over-2-billion-ximalaya-merger/chl7VcFRbzk">Tencent Expands Audio Empire With $2.4B Ximalaya Merger: Retail Turns Optimistic</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Stock market down on a black background. | Image source: Yuichiro Chino via Getty Images

Ernexa Stock Drops On 1-For-15 Reverse Stock Split To Regain Nasdaq Compliance: Retail Sentiment Improves But Stays Bearish

As of Tuesday, the company had 110.4 million shares of common stock issued and outstanding, which it anticipates will result in approximately 7.4 million shares on a split-adjusted basis.

This account has been verified as an official ERNA representative.

Verified Account

Ernexa Therapeutics

Ernexa Therapeutics, Inc. engages in the provision of cell engineering therapies. It is involved in the development of mRNA cell engineering technologies to repair cellular dysfunction and treat a range of therapeutic indications. The company was founded in 1984 and is headquartered in Cambridge, MA.

Ernexa Therapeutics Inc.

Buying for a long-term investment

Buying for a short-term trade

Trading around the volatility

Avoiding it 

Cerebras ($CRBS) IPO day is Thursday, how are you playing it?  
 
Drop a comment with your strategy.

Current Price	$11.65
Prev Close	$12.14
Open	$11.60
Dividend Yield	0.00%
50-Day Moving Average	$6.00
Beta	0.94
Avg. Volume	27,093.72
PE Ratio	-0.40

52-Week High	$93.75
52-Week Low	$3.18
Market Capitalization	$14.16M
EPS (Annual)	-$55.89
Price to Book	2.06
Revenue Per Employee	$0.00

ERNA
Ernexa Therapeutics Inc.

Feed

News

Sentiment

Fundamentals

Info

Latest ERNA News

ERNAErnexa Therapeutics Inc.